| Literature DB >> 35802738 |
Lucia Magee1, Felicity Knights1,2, Doug G J Mckechnie3, Roaa Al-Bedaery1, Mohammad S Razai1.
Abstract
INTRODUCTION: COVID-19 vaccination effectively reduces severe disease and death from COVID-19. However, both vaccine uptake and intention to vaccinate differ amongst population groups. Vaccine hesitancy is highest amongst specific ethnic minority groups. There is very limited understanding of the barriers and facilitators to COVID-19 vaccine uptake in Black and South Asian ethnicities. Therefore, we aimed to explore COVID-19 vaccination hesitancy in primary care patients from South Asian (Bangladeshi/Pakistani) and Black or Black British/African/Caribbean/Mixed ethnicities.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35802738 PMCID: PMC9269906 DOI: 10.1371/journal.pone.0270504
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.752
Demographic and clinical characteristics of the 38 participants interviewed.
|
|
|
| 50.5 (19–82) | |
|
| 22 (58%) |
|
| |
| Black/Black British -African | 11 (29%) |
| Black/Black British -Caribbean | 10 (26.3%) |
| Asian/Asian British Pakistani | 8 (21%) |
| Asian/Asian British Bangladeshi | 4 (10.5%) |
| Mixed Caribbean/White | 4 (10.5%) |
| Mixed African/White | 1 (2.6%) |
|
| |
| UK | 19 (50%) |
| Africa | 7 (18.4%) |
| Caribbean | 5 (13%) |
| South Asia | 7 (18.5%) |
|
| |
| None | 9 (24%) |
| GCSE/O Levels | 5 (13.2%) |
| A-Levels/BTEC/NVQ | 10 (26.3%) |
| Bachelors | 5 (13%) |
| Masters | 5 (13%) |
| Other | 4 (10.5%) |
|
| |
| Hypertension | 13 (34%) |
| Diabetes | 7 (18.4%) |
| Stroke | 2 (5.2%) |
| Depression | 2 (5.2%) |
| Anxiety | 4 (10.5%) |
| None of the above | 10 (26.3%) |
|
| |
| Yes | 37 (97%) |
| No | 1 (3%) |
|
| |
| Yes | 32 (84%) |
| No | 6 (16%) |
|
| |
| Yes | 10 (26%) |
| No | 14 (37%) |
| Not sure | 14 (37%) |
*As reported by the patient.
Key Implementation messages: Addressing participants’ views on barriers and facilitators of COVID-19 vaccine uptake.
| Factors influencing uptake | Opportunities to address this in primary care / the community | Considerations & Resources for practice: |
|---|---|---|
|
| Addressing fears directly about speed of vaccinxfe roll out | • Explain vaccination research process why this was quicker than anticipated. |
|
| Tailored information, addressing how different ethnicities were involved in the study | • Discussing concerns and sharing information with specific information about the demographics of participants in the trials. |
|
| Understand previous misinformation exposure in order to address concerns directly. | • Seek to understand misinformation exposure and how this has informed current thinking and hesitancy around vaccination |
|
| Opportunity for information provision from trusted Health Care Professionals | • Opportunistic vaccine promotion during health contacts |
|
| Channelling communication through communities & religious groups | • Identify trusted local leadership and engage in reaching local communities |
|
| Utilising inter-generational information transfer | • Ensuring vaccination promotion messages reach patients across age-groups and encourage sharing of information provision with family members across generations. |
|
| Highlight incentives for vaccination such as travel and protection of family members | • Explore potential vaccination benefits and their impact for the patient. |